CSF1R and neoplasm: Our earlier studies demonstrated that anti-CSF1R treatment does not alter the recruitment of monocyte macrophages into inflammatory sites, but does greatly reduce the large numbers of tumour-associated macrophages (TAMs) detected using the MacGreen transgene [11].